Agendia Study Demonstrates MammaPrint® and BluePrint® Capture Full Spectrum of Early Breast Cancer Biology, Providing Opportunity for Highly Individualized Treatment
New analysis in peer-reviewed journal Genes, Chromosomes and Cancer Read More
Agendia to Provide First Digital MammaPrint Capability to Brazil
AI solution will expand Agendia’s testing platform in the Brazilian Read More
Agendia Partners with Illumina to Expand Genomic Testing in Breast Cancer Care
Multi-year partnership to advance the use of next-generation sequencing for Read More
Agendia Appoints Suja Chandrasekaran and Scott Mendel to Board of Directors, Strengthening Advisory Group to Support Company Momentum
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – January 6, 2022 Read More
Agendia Spotlight Poster at SABCS 2021 Confirms Utility of BluePrint as Biomarker Subtyping Test to Guide Neoadjuvant Chemotherapy Decisions
Additional research from the real-world FLEX Registry focuses on age Read More
Analysis Presented at SABCS 2021 Confirms MammaPrint and BluePrint Predict Outcomes Following Neoadjuvant Chemotherapy
Data signal importance of serial genomic testing in order to Read More
Agendia Presents Data at SABCS 2021 Showing MammaPrint and BluePrint More Robustly Identify Genomic Differences in HR+ HER2- Breast Cancers in Black and White Women Beyond Clinical Factors
ER+ tumors reclassified by BluePrint as Basal-type occur at a Read More
Agendia’s MammaPrint Test is the First to Demonstrate the Ability to Predict Benefit from Extended Endocrine Treatment in NSABP B-42 Trial
MammaPrint was the only test to predict significant 36% and Read More
Analysis of MINDACT Study Confirms MammaPrint Accurately Identifies Extremely Indolent Ultra Low Risk Breast Cancers
Oral presentation at ASCO 2021 highlights long term data with Read More
Agendia Presents Data from Innovative FLEX Study at ASCO 2021 Showing MammaPrint and BluePrint Utility in Wide Variety of Patient Populations
Transcriptomic differences found between Luminal tumors in African American and Read More
